Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma’s new strategy will be to test some of those drugs across neurology and immunology indications.
“A new focus area first in 2025 will be to study potential new applications of incretin biology across diseases in neuroscience and immunology,” Lilly’s chief scientific officer Daniel Skovronsky, M.D., Ph.D., said during a Feb. 6 investor call. “With a pipeline of incretins in clinical development and deep scientific expertise in this space, Lilly is well positioned to match the biologic properties of specific molecules…